CN Patent

CN115516092B — 血管生成素样3(ANGPTL3)的siRNA及其用途

Assigned to Eddingpharm (Zhuhai) Co.,Ltd. · Expires 2025-05-16 · 1y expired

What this patent protects

提供一种血管生成素样3(ANGPTL3)的siRNA及其用途。通过设计合适的特异性小干扰RNA序列以及siRNA缀合物，靶向ANGPTL3，通过降解细胞中ANGPTL3基因的转录物，从而降低ANGPTL3蛋白表达量，所述的siRNA可用于预防和/或治疗血脂异常疾病。

USPTO Abstract

提供一种血管生成素样3(ANGPTL3)的siRNA及其用途。通过设计合适的特异性小干扰RNA序列以及siRNA缀合物，靶向ANGPTL3，通过降解细胞中ANGPTL3基因的转录物，从而降低ANGPTL3蛋白表达量，所述的siRNA可用于预防和/或治疗血脂异常疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN115516092B
Jurisdiction
CN
Classification
—
Expires
2025-05-16
Drug substance claim
No
Drug product claim
No
Assignee
Eddingpharm (Zhuhai) Co.,Ltd.
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.